COMMUNIQUÉS West-GlobeNewswire

MSInsight annonce une levée de fonds d’amorçage de 1,6 M€ pour révolutionner le diagnostic des cancers MSI

10/03/2025 - 17:45

Communiqué de presse Paris, le 12 mars 2025 – MSInsight, start-up innovante spécialisée dans la médecine de précision en oncologie, annonce la réussite de son tour de financement d’amorçage d'un montant de 1,6 million d [...]

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

10/03/2025 - 17:40

Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations. Approach [...]

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

10/03/2025 - 16:18

Psyence Group settles Debt for Shares TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the " Company ") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd [...]

Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025

10/03/2025 - 16:00

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual [...]

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

10/03/2025 - 16:00

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 10 March 2025 at 17.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc.

10/03/2025 - 15:30

MESQUITE, NV, March 10, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the [...]

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

10/03/2025 - 15:13

Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical [...]

Transactions under Novonesis’ share buyback program

10/03/2025 - 15:08

Please read the announcement in PDF Attachment 2025_10_Share_buyback_program

First Patient Enrolled in Merit Medical’s PREEMIE Study

10/03/2025 - 14:25

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE [...]

PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

10/03/2025 - 14:24

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

10/03/2025 - 14:17

Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 mars 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

10/03/2025 - 14:15

Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 mars 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

10/03/2025 - 14:15

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc . [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

10/03/2025 - 14:14

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to [...]

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

10/03/2025 - 14:00

Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming [...]

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

09/03/2025 - 01:00

LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based [...]

Curia annonce un refinancement stratégique visant à soutenir la poursuite de sa croissance

08/03/2025 - 19:54

ALBANY, New York, 08 mars 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui le refinancement de [...]

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08/03/2025 - 19:00

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral [...]

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

08/03/2025 - 19:00

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were [...]